3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
7
Tumor-Agnostic
6
Thoracic
6
Gastrointestinal
5
Head & Neck
3
Gynecologic
3
Breast
3
Endocrine
2
Dermatologic
2
Sarcoma
1
NET
1
CNS
1
Conditions
Neuroendocrine Tumors
4
Carcinoma, Merkel Cell
2
Neoplasms
1
Carcinoma, Neuroendocrine
1
Carcinoma
1
Interventions
Everolimus
5
Sunitinib
4
lutetium Lu 177 dotatate
2
PM 01183
2
Octreotide
2
Doxorubicin
2
trifluridine tipiracil drug combination
1
telotristat ethyl
1
repotrectinib
1
pralsetinib
1
pegfilgrastim
1
pasireotide
1
motesanib diphosphate
1
epothilone B
1
dactolisib
1
copper dotatate CU-64
1
batifiban
1
avelumab
1
alectinib
1
Temozolomide
1
TKM-080301
1
Surveys and Questionnaires
1
SNX-5422
1
Referral and Consultation
1
Radiomics
1
Quality of Life
1
Patient Reported Outcome Measures
1
Oxaliplatin
1
Molecular Diagnostic Techniques
1
Lutetium-177
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
avelumab
×
NET
×
Clear all
NCT03352934
2022-02-25
AveNEC
Johannes Gutenberg University Mainz
Phase 2
Completed
60 enrolled